Changes in Disposition of Ezetimibe and Its Active Metabolites Induced by Impaired Hepatic Function: The Influence of Enzyme and Transporter Activities

Ezetimibe (EZE) is a selective cholesterol absorption inhibitor. Hepatic impairment significantly increases the systemic exposure of EZE and its main active phenolic glucuronide, EZE-Ph. Although changes in efflux transporter activity partly explain the changes in EZE-Ph pharmacokinetics, the causes...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Ningjie, Wang, Hong, Qin, Hua, Guo, Zitao, Xue, Hao, Hu, Jiafeng, Chen, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785202/
https://www.ncbi.nlm.nih.gov/pubmed/36559237
http://dx.doi.org/10.3390/pharmaceutics14122743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785202/
https://www.ncbi.nlm.nih.gov/pubmed/36559237
http://dx.doi.org/10.3390/pharmaceutics14122743

Ejemplares similares